Molecular topology as novel strategy for discovery of drugs with Aβ lowering and anti-aggregation dual activities for Alzheimer's disease

Jun Wang, David Land, Kenjiro Ono, Jorge Galvez, Wei Zhao, Prashant Vempati, John W. Steele, Alice Cheng, Masahito Yamada, Samara Levine, Paolo Mazzola, Giulio M. Pasinetti

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Background and Purpose: In this study, we demonstrate the use of Molecular topology (MT) in an Alzheimer's disease (AD) drug discovery program. MT uses and expands upon the principles governing the molecular connectivity theory of numerically characterizing molecular structures, in the present case, active anti-AD drugs/agents, using topological descriptors to build models. Topological characterization has been shown to embody sufficient molecular information to provide strong correlation to therapeutic efficacy. Experimental Approach: We used MT to include multiple bioactive properties that allows for the identification of multifunctional single agent compounds, in this case, the dual functions of β-amyloid (Aβ)-lowering and anti-oligomerization. Using this technology, we identified and designed novel compounds in chemical classes unrelated to current anti-AD agents that exert dual Aβ lowering and anti-Aβ oligomerization activities in animal models of AD. AD is a multifaceted disease with different pathological features. Conclusion and Implications: Our study, for the first time, demonstrated that MT can provide novel strategy for discovering drugs with Aβ lowering and anti-aggregation dual activities for AD.

Original languageEnglish
Article numbere92750
JournalPLoS ONE
Volume9
Issue number3
DOIs
StatePublished - 26 Mar 2014

Fingerprint

Dive into the research topics of 'Molecular topology as novel strategy for discovery of drugs with Aβ lowering and anti-aggregation dual activities for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this